MARINER - Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk

Purpose: A comparison of rivaroxaban to placebo in high-risk patients for prevention of post-discharge venous thromboembolism (VTE) events and death.

Trial Design: Phase 3, randomized 1:1, double-blinded, placebo-controlled trial. Patients treated for 45 days after discharge and followed for 30 days. Rivaroxaban 7.5 mg or 10 mg daily (based on creatinine clearance) or placebo. N=12,019.

Primary Endpoints:

Efficacy: Time to first occurrence of symptomatic VTE events and VTE-related death; days 1-45.

Safety: Major bleeding

Secondary: non-fatal VTE

	Symptomatic VTE, VTE-related death P=0.136	Major Bleeding P=0.124	Non-fatal VTE P=0.033
placebo	1.10%	0.15%	0.42%
rivaroxaban	0.83%	0.28%	0.18%

Results: The risk for symptomatic VTE or of VTE-related death wasn't significantly lower with rivaroxaban compared to placebo when given for 45 days after discharge.

Presented by: Alex SPYROPOULOS, ESC 2018 Munich, Germany